Cadmium chloride enhances cisplatin sensitivity in osteosarcoma cells by reducing FOXM1 expression

Hu,Konghe; Xie,Wenquan; Ni,Songjia; Yan,Shumin; Tian,Gaoqiang; Qi,Weizhong; Duan,Yang

doi:10.3892/or.2020.7632

Cadmium chloride enhances cisplatin sensitivity in osteosarcoma cells by reducing FOXM1 expression

Authors:
- Konghe Hu
- Wenquan Xie
- Songjia Ni
- Shumin Yan
- Gaoqiang Tian
- Weizhong Qi
- Yang Duan
View Affiliations

Affiliations: Department of Spine Surgery, The Affiliated Yuebei People's Hospital of Shantou University Medical College, Shaoguan, Guangdong 512025, P.R. China, Department of Orthopedics, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280, P.R. China
Published online on: June 4, 2020 https://doi.org/10.3892/or.2020.7632
Pages: 650-660
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is a highly malignant disease and is associated with a poor patient prognosis and a high mortality rate. Disease prognosis significantly correlates with chemotherapeutic responses. Cadmium is a heavy metal with specific effects on bone, but its benefits for osteosarcoma treatment have not been characterized. In the present study, cadmium chloride was used to treat MG63 osteosarcoma cells, and their gene expression profiles were assessed by GeneChip technology. We found that forkhead box protein M1 (FOXM1) was downregulated by cadmium chloride, and lentiviral‑mediated silencing of FOXM1 confirmed a role for this factor in the cisplatin resistance of MG63 cells. In nude mice, cadmium chloride enhanced the sensitivity of osteosarcoma to cisplatin, an effect mediated by FOXM1. Collectively, these data indicate that cadmium chloride can alter the sensitivity of osteosarcoma cells to cisplatin through FOXM1, highlighting it as a potential therapeutic target and prognostic factor for osteosarcoma.

View Figures

View References

1	Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC and Egeler RM: Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand? Eur J Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kansara M, Teng MW, Smyth MJ and Thomas DM: Translational biology of osteosarcoma. Nat Rev Cancer. 14:722–735. 2014. View Article : Google Scholar : PubMed/NCBI
3	Ritter J and Bielack SS: Osteosarcoma. Ann Oncol. 21 (Suppl 7):vii320–325. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ferrari S and Serra M: An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother. 16:2727–2736. 2015. View Article : Google Scholar : PubMed/NCBI
5	Moriarity BS, Otto GM, Rahrmann EP, Rathe SK, Wolf NK, Weg MT, Manlove LA, LaRue RS, Temiz NA, Molyneux SD, et al: A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Na Genet. 47:615–624. 2015. View Article : Google Scholar
6	Baranski Z, Booij TH, Cleton-Jansen AM, Price LS, van de Water B, Bovée JV, Hogendoorn PC and Danen EH: Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. J Pathol. 236:348–359. 2015. View Article : Google Scholar : PubMed/NCBI
7	Holmboe L, Andersen AM, Mørkrid L, Slørdal L and Hall KS: High dose methotrexate chemotherapy: Pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 73:106–114. 2012. View Article : Google Scholar : PubMed/NCBI
8	Wallin M, Barregard L, Sallsten G, Lundh T, Karlsson MK, Lorentzon M, Ohlsson C and Mellström D: Low-level cadmium exposure is associated with decreased bone mineral density and increased risk of incident fractures in elderly men: The MrOS Sweden Study. J Bone Miner Res. 31:732–741. 2016. View Article : Google Scholar : PubMed/NCBI
9	Akesson A, Bjellerup P, Lundh T, Lidfeldt J, Nerbrand C, Samsioe G, Skerfving S and Vahter M: Cadmium-induced effects on bone in a population-based study of women. Environ Health Perspect. 114:830–834. 2006. View Article : Google Scholar : PubMed/NCBI
10	Coogan TP, Achanzar WE and Waalkes MP: Spontaneous transformation of cultured rat liver (TRL 1215) cells is associated with down-regulation of metallothionein: Implications for sensitivity to cadmium cytotoxicity and genotoxicity. J Environ Pathol Toxicol Oncol. 19:261–273. 2000.PubMed/NCBI
11	Benbrahim-Tallaa L, Waterland RA, Dill AL, Webber MM and Waalkes MP: Tumor suppressor gene inactivation during cadmium-induced malignant transformation of human prostate cells correlates with overexpression of de novo DNA methyltransferase. Environ Health Perspect. 115:1454–1459. 2007. View Article : Google Scholar : PubMed/NCBI
12	Xie D and Sheng Z: Low-level cadmium exposure and bone health. J Bone Miner Res. 32:4192017. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Kahler SC: Integrating cultural competence: Animal health, food safety ultimately benefit as AVMA incorporates cultural competence in CE. J Am Vet Med Assoc. 242:1186–1187. 2013.PubMed/NCBI
15	Rice ASC, Morland R, Huang W, Currie GL, Sena ES and Macleod MR: Transparency in the reporting of in vivo pre-clinical pain research: The relevance and implications of the ARRIVE (Animal research: Reporting in vivo experiments) guidelines. Scand J Pain. 4:58–62. 2013. View Article : Google Scholar : PubMed/NCBI
16	Picci P: Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar : PubMed/NCBI
17	Jaffe N: Osteosarcoma: Review of the past, impact on the future. The American experience. Cancer Treat Res. 152:239–262. 2009. View Article : Google Scholar : PubMed/NCBI
18	Do SI, Jung WW, Kim HS and Park YK: The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. Int J Oncol. 34:797–803. 2009.PubMed/NCBI
19	Man TK, Lu XY, Jaeweon K, Perlaky L, Harris CP, Shah S, Ladanyi M, Gorlick R, Lau CC and Rao PH: Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer. 4:452004. View Article : Google Scholar : PubMed/NCBI
20	Lau CC, Harris CP, Lu XY, Perlaky L, Gogineni S, Chintagumpala M, Hicks J, Johnson ME, Davino NA, Huvos AG, et al: Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes, Chromos Cancer. 39:11–21. 2004. View Article : Google Scholar
21	Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment-Where do we stand? A state of the art review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
22	Martelli L, Di Mario F, Botti P, Ragazzi E, Martelli M and Kelland L: Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status. Biochem Pharmacol. 74:20–27. 2007. View Article : Google Scholar : PubMed/NCBI
23	Liang Q, Dexheimer TS, Zhang P, Rosenthal AS, Villamil MA, You C, Zhang Q, Chen J, Ott CA, Sun H, et al: A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. Nat Chem Biol. 10:298–304. 2014. View Article : Google Scholar : PubMed/NCBI
24	Levy JM, Towers CG and Thorburn A: Targeting autophagy in cancer. Nat Rev Cancer. 17:528–542. 2017. View Article : Google Scholar : PubMed/NCBI
25	Shibata A, Moiani D, Arvai AS, Perry J, Harding SM, Genois MM, Maity R, van Rossum-Fikkert S, Kertokalio A, Romoli F, et al: DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities. Mol Cell. 53:7–18. 2014. View Article : Google Scholar : PubMed/NCBI
26	Koo CY, Muir KW and Lam EW: FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta. 1819:28–37. 2012. View Article : Google Scholar : PubMed/NCBI
27	Uddin S, Hussain AR, Ahmed M, Siddiqui K, Al-Dayel F, Bavi P and Al-Kuraya KS: Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma. Haematologica. 97:1092–1100. 2012. View Article : Google Scholar : PubMed/NCBI
28	Wang M and Gartel AL: The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA. Oncotarget. 2:1218–1226. 2011. View Article : Google Scholar : PubMed/NCBI
29	Pandit B and Gartel AL: FoxM1 knockdown sensitizes human cancer cells to proteasome inhibitor-induced apoptosis but not to autophagy. Cell Cycle. 10:3269–3273. 2011. View Article : Google Scholar : PubMed/NCBI
30	Nestal de Moraes G, Bella L, Zona S, Burton MJ and Lam EW: Insights into a critical role of the FOXO3a-FOXM1 axis in DNA damage response and genotoxic drug resistance. Curr Drug Targets. 17:164–177. 2016. View Article : Google Scholar : PubMed/NCBI
31	Peake BF, Eze SM, Yang L, Castellino RC and Nahta R: Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling. Oncotarget. 8:94393–94406. 2017. View Article : Google Scholar : PubMed/NCBI
32	Khongkow P, Karunarathna U, Khongkow M, Gong C, Gomes AR, Yagüe E, Monteiro LJ, Kongsema M, Zona S, Man EP, et al: FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. Oncogene. 33:4144–4155. 2014. View Article : Google Scholar : PubMed/NCBI
33	Zerlin M, Julius MA and Kitajewski J: Wnt/Frizzled signaling in angiogenesis. Angiogenesis. 11:63–69. 2008. View Article : Google Scholar : PubMed/NCBI
34	Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:609–619. 1993. View Article : Google Scholar : PubMed/NCBI